LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

Search

IQVIA Holdings Inc

Gesloten

SectorGezondheidszorg

225.03 3.6

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

215.38

Max

225.63

Belangrijke statistieken

By Trading Economics

Inkomsten

66M

332M

Verkoop

83M

4.1B

K/W

Sectorgemiddelde

29.687

106.172

Winstmarge

8.098

Werknemers

91,000

EBITDA

102M

883M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+9.06% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-683M

37B

Vorige openingsprijs

221.43

Vorige sluitingsprijs

225.03

Nieuwssentiment

By Acuity

27%

73%

59 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

IQVIA Holdings Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

20 nov 2025, 23:07 UTC

Marktinformatie

Evidence Of Broad Australian Economic Upswing Mounts -- Market Talk

20 nov 2025, 22:22 UTC

Marktinformatie

Auckland Airport Has Edge Over Transurban In Infrastructure Stocks -- Market Talk

20 nov 2025, 22:08 UTC

Marktinformatie

Revenues of Texas Battery Projects Drop Sharply -- Market Talk

20 nov 2025, 21:57 UTC

Winsten

Walmart Reports Strong Sales Growth, Raises Outlook -- 5th Update

20 nov 2025, 21:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

20 nov 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

20 nov 2025, 21:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Health Care Roundup: Market Talk

20 nov 2025, 21:50 UTC

Marktinformatie
Winsten

Financial Services Roundup: Market Talk

20 nov 2025, 21:31 UTC

Winsten

Nvidia's Strong Results Show AI Fears Are Premature -- Update

20 nov 2025, 21:23 UTC

Winsten
Acquisities, Fusies, Overnames

These Stocks Moved the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Alphabet, Palo Alto Networks, and More -- Barrons.com

20 nov 2025, 21:07 UTC

Winsten

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

20 nov 2025, 21:06 UTC

Winsten

Webull 3Q Rev $156.9M >BULL

20 nov 2025, 21:06 UTC

Winsten

Webull 3Q EPS 7c >BULL

20 nov 2025, 21:05 UTC

Winsten

Intuit 1Q Sales Jump, CFO Cites AI Demand From Mid-Sized Businesses -- Interview

20 nov 2025, 21:04 UTC

Winsten

Mid-Sized Businesses Want to Automate Tasks With AI, Intuit CFO Says >INTU

20 nov 2025, 21:04 UTC

Winsten

Intuit's AI Offerings Attracted More Mid-Sized Businesses in 1Q, CFO Says >INTU

20 nov 2025, 21:04 UTC

Winsten

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

20 nov 2025, 21:00 UTC

Winsten

Intuit Sees 2Q Rev $4.52B-$4.55B >INTU

20 nov 2025, 21:00 UTC

Winsten

Intuit Sees FY26 GAAP Operating Income $5.78B to $5.86B

20 nov 2025, 21:00 UTC

Winsten

Intuit Sees 2Q Adj EPS $3.63-Adj EPS $3.68 >INTU

20 nov 2025, 21:00 UTC

Winsten

Intuit Expects FY26 Global Business Solutions Rev Growth of 15.5% to 16.5%, Excluding Mailchimp

20 nov 2025, 21:00 UTC

Winsten

Intuit Expects FY26 Consumer Rev Growth of 8% to 9%

20 nov 2025, 21:00 UTC

Winsten

Intuit Expects FY26 Global Business Solutions Rev Growth of 14% to 15%

20 nov 2025, 21:00 UTC

Winsten

Intuit Backs FY26 Rev $21B-$21.19B >INTU

20 nov 2025, 21:00 UTC

Winsten

Intuit Backs FY26 Adj EPS $22.98-Adj EPS $23.18 >INTU

20 nov 2025, 21:00 UTC

Winsten

Intuit 1Q Consumer Rev $894M

20 nov 2025, 21:00 UTC

Winsten

Intuit Sees 2Q EPS $1.76-EPS $1.81 >INTU

20 nov 2025, 21:00 UTC

Winsten

Intuit Backs FY26 Guidance

20 nov 2025, 21:00 UTC

Winsten

Intuit Backs FY26 EPS $15.49-EPS $15.69 >INTU

20 nov 2025, 21:00 UTC

Winsten

Intuit 1Q Global Business Solutions Rev $3B

Peer Vergelijking

Prijswijziging

IQVIA Holdings Inc Prognose

Koersdoel

By TipRanks

9.06% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 236.79 USD  9.06%

Hoogste 265 USD

Laagste 200 USD

Gebaseerd op 16 Wall Street-analisten die 12-maands prijsdoelen bieden voor IQVIA Holdings Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

16 ratings

13

Buy

3

Hold

0

Sell

Technische score

By Trading Central

150.68 / 153.45Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Neutral Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

59 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
help-icon Live chat